Using rIL-2 and FAA to Treat Advanced Melanoma
Author Information
Author(s): N. Thatcher, H. Dazzil, M. Mellor, A. Ghosh, B. Carrington, R.J. Johnson, E.M. Loriaux, R.P. Craig
Primary Institution: Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester
Hypothesis
Does the combination of recombinant interleukin-2 (rIL-2) and flavone acetic acid (FAA) improve treatment outcomes in patients with advanced malignant melanoma?
Conclusion
The addition of FAA to rIL-2 did not significantly improve treatment outcomes compared to rIL-2 alone.
Supporting Evidence
- Five patients had a complete or partial response to treatment.
- Eleven patients remained alive at 6-17 months after treatment.
- 74 courses of treatment were administered with generally mild side effects.
Takeaway
Doctors tried a new treatment for skin cancer using two medicines, but it didn't work better than just one medicine alone.
Methodology
Patients received rIL-2 and FAA in a structured treatment regimen over several courses, with evaluations of response and toxicity.
Limitations
The study had a small sample size and did not include a control group receiving only rIL-2.
Participant Demographics
19 male and 15 female patients with a median age of 45 years.
Want to read the original?
Access the complete publication on the publisher's website